The prognosis of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) is critical in clinical management. We aimed to assess the prognostic e cacy of superoxide dismutase 2 (SOD2) for 90-day mortality in HBV-ACLF patients. The expression patterns of SOD2 in peripheral blood mononuclear cells (PBMCs) were examined in a derivation set (n = 82) by quantitative real-time polymerase chain reaction (RT-qPCR). The results were further validated in a validation set (n = 35). The expression levels of SOD2 were signi cantly decreased in the derivation set compared to those with chronic hepatitis B (CHB) or the healthy controls (HCs) (P < 0.001). In HBV-ACLF patients, SOD2 levels were negatively correlated with serum total bilirubin (TBIL) (rs = -0.43, P < 0.001) and model for end-stage liver disease (MELD) scores (rs = -0.22, P = 0.047), but positively correlated with alkaline phosphatase (AKP) (rs = 0.23, P = 0.034). SOD2 was identi ed as an independent risk factor for 90-day mortality in HBV-ACLF patients (hazard ratio: 0.124, 95% con dence interval: 0.059-0.261, P < 0.001). SOD2 yielded a larger area under the receiver operating characteristic curve (AUROC) than the MELD score in predicting 90-day mortality (0.914 versus 0.712, P < 0.001). Kaplan-Meier analysis revealed a favorable overall survival (OS) for the SOD2 high expression group compared with the SOD2 low expression group in both the derivation and validation sets (P < 0.001). SOD2 has promising potential as a predictor of 90-day mortality in patients with HBV-ACLF. synthesis kit (Fermentas, Vilnius, Lithuania). qRT-PCR was performed using SYBR® Premix ExTaqTM (TaKaRa), with β-actin serving as the internal control. The reaction was performed in a total volume of 10 µL, which included 4.1 µL of RNase-free ddH2O, 0.2 µL of speci c forward and reverse primers, 5 µL of SYBR Green, and 0.5 µL of cDNA, under the following conditions: initial denaturation at 95℃ for 10 minutes, then 40 cycles of denaturation at 95 °C for 5 seconds, annealing at 58 °C for 30 seconds and extension at 72 °C for 30 seconds. The primers used have been described in a previous study [17]: SOD2 forward, 5′-GAGAAGTACCAGGAGGCGTTG-3′; SOD2 reverse, 5′-GAGCCTTGGACACCAACAGAT-3′; β-actin forward, 5′-AGAGCTACGAGCTGCCTGAC-3′; β-actin reverse, 5′-AGCACTGTGTTGGCGTACAG-3′. The relative expression of SOD2 was calculated using the 2 − ΔΔCT method. All ampli cation reactions were performed in triplicate. Statistical AnalysisStatistical analyses were performed using IBM SPSS Statistics (version 26.0; IBM Statistics, Armonk, NY) and R software (version 4.0.2 for Windows; the R foundation for statistical computing, Vienna, Austria). The demographic characteristics are presented as medians (interquartile range) or percentages. The Mann-Whitney U test was used to quantitative variables, while the chi-square test was used to categorical variables. Spearman rank correlation analysis was used to assess the associations between SOD2 levels and clinical variables. Using Cox proportional hazard regr...
The prognosis of hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) is critical in clinical management. We aimed to assess the prognostic efficacy of superoxide dismutase 2 (SOD2) for 90-day mortality in HBV-ACLF patients. The expression patterns of SOD2 in peripheral blood mononuclear cells (PBMCs) were examined in a derivation set (n = 82) by quantitative real-time polymerase chain reaction (RT-qPCR). The results were further validated in a validation set (n = 35). The expression levels of SOD2 were significantly decreased in the derivation set compared to those with chronic hepatitis B (CHB) or the healthy controls (HCs) (P < 0.001). In HBV-ACLF patients, SOD2 levels were negatively correlated with serum total bilirubin (TBIL) (rs = -0.43, P < 0.001) and model for end-stage liver disease (MELD) scores (rs = -0.22, P = 0.047), but positively correlated with alkaline phosphatase (AKP) (rs = 0.23, P = 0.034). SOD2 was identified as an independent risk factor for 90-day mortality in HBV-ACLF patients (hazard ratio: 0.124, 95% confidence interval: 0.059-0.261, P < 0.001). SOD2 yielded a larger area under the receiver operating characteristic curve (AUROC) than the MELD score in predicting 90-day mortality (0.914 versus 0.712, P < 0.001). Kaplan-Meier analysis revealed a favorable overall survival (OS) for the SOD2 high expression group compared with the SOD2 low expression group in both the derivation and validation sets (P < 0.001). SOD2 has promising potential as a predictor of 90-day mortality in patients with HBV-ACLF.
Background: For patients with cirrhosis, early diagnosis is the key to delay the development of liver fibrosis and improve prognosis. TNFSF15, a gene encoding TNF-like ligand 1A (TL1A) as a susceptibility gene for hepatic fibrosis. Aim: This study aimed to investigate the clinical significance of TL1A and DR3 in the development of cirrhosis and fibrosis. Methods: All total of 200 patients, including 107 with HBV-associated LC patients, 63 CHB and 30 healthy controls. Then we were analysed the expression of TL1A, DcR3 and other inflammatory cytokines associated with liver fibrosis by using quantify DNA methylation, qPCR and Enzyme-linked immunosorbent assay in serum and PBMCs.Results: PBMCs TL1A methylation level was significantly lower in patients with HBV-associated LC than the other groups while mRNA level of TL1A was significantly higher in LC group. In addition, serum TL1A and DcR3 expression level was increased in the LC patients. Conclusions: Hypomethylation of the TL1A promoter is present in HBV-associated LC, and TL1A and DR3 are highly expressed in HBV-associated cirrhosis. These results indicate that TL1A and DR3 may play an important role in the pathogenesis of LC and TL1A methylation levels may serve as a noninvasive biomarker for early diagnosis and progression of LC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.